Khalid Islam
Khalid Islam's purchase track record
Khalid Islam has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/9/2024 | GANX | $50K | +125.8% | +166.1% | +12.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Processa Files Prospectus for 306.5M Share Offering. Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.
Transaction History
| GANX | ▲ Buy | Open Market | 50,000 | $50K | 8/9/2024 | View on chart |
| FENC | ▲ Buy | Option Exercise | 133,333 | $308K | 11/16/2023 | View on chart |
| FENC | ▲ Buy | Option Exercise | 10,000 | $27K | 11/16/2023 | View on chart |
| FENC | ▲ Buy | Option Exercise | 50,000 | $56K | 11/16/2023 | View on chart |
| FENC | ▲ Buy | Option Exercise | 20,492 | $50K | 11/16/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 4,392 | — | 3/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Gain Therapeutics Appoints CEO Gene Mack As Interim CFO
Gain Therapeutics has named CEO Gene Mack as the interim Chief Financial Officer, effective October 1. He is succeeding Gianluca Fuggetta in the role. This leadership change occurs while the stock trades significantly below the average analyst target price.
Gain Therapeutics Appoints CEO Gene Mack As Interim CFO. Gain Therapeutics has named CEO Gene Mack as the interim Chief Financial Officer, effective October 1. He is succeeding Gianluca Fuggetta in the role. This leadership change occurs while the stock trades significantly below the average analyst target price.